Ensoma is expanding the reach of the curative power of genomic medicine by pioneering a next-generation in vivo approach using its Engenious™ vectors. Ensoma’s vectors are designed to deliver a diverse range of gene modification technologies without the need for stem cell collection or prior myeloablative conditioning (e.g. chemotherapy). Learn more at www.ensoma.com.
Location: United States, Massachusetts, Boston
Investors 1
| Date | Name | Website |
| - | F-Prime Ca... | fprimecapi... |
Mentions in press and media 2
| Date | Title | Description | Source |
| 16.05.2023 | Ensoma Closes Series B Extension, Bringing Total Round to $1... | - | fprimecapi... |
| 05.01.2023 | Ensoma Announces $85 Million Financing and Agreement to Acqu... | - | fprimecapi... |